- Lot-matched certificate of analysis
- Ships next business day, tracked
Ventfort (Vascular Bioregulator)
Vessel-derived peptide complex in capsules, from the Khavinson cytomax series
- FormOral research capsules in a sealed bottle with tamper-evident closure
- Research areasEndothelial cell models, vessel-wall structure, vascular ageing, gene and protein expression endpoints
Overview
Ventfort is the vascular member of the natural peptide bioregulator series developed at the St Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. Unlike the synthetic short peptides in the same programme, it is a tissue-derived preparation: a low-molecular-weight peptide complex obtained by fractionating vessel-wall tissue from young animals, then purified and encapsulated. It is therefore a mixture characterised by fraction profile rather than a single sequence with a formula and molecular weight.
The organisation of the series is worth understanding before designing an experiment with it. Each organ preparation — vascular, cardiac, pineal, thymic and so on — was studied first as an extract, and in several cases a defined short peptide was later identified and synthesised as a research surrogate. Ventfort occupies the extract position for vascular tissue, while Vesugen supplies the corresponding defined tripeptide, Lys-Glu-Asp. Comparing the two is one of the more common study designs in this area.
Specifications
Supply & purity
- Form
- Oral research capsules in a sealed bottle with tamper-evident closure
Additional detail
- Available counts
- 20 capsules, 60 capsules
- Product type
- Tissue-derived peptide complex (mixture), not a single-sequence peptide
- Source material
- Vessel-wall tissue of young animals, fractionated and purified
- Composition
- Water-soluble low-molecular-weight peptide fractions with associated amino acids
- Molecular weight range
- Peptide fractions typically below approximately 10 kDa
- Series
- Khavinson natural peptide bioregulators (cytomax line)
- Tissue association
- Vascular endothelium and vessel wall
- Synthetic counterpart
- Vesugen (Lys-Glu-Asp, KED) — the defined tripeptide assigned to vascular tissue
- Research areas
- Endothelial cell models, vessel-wall structure, vascular ageing, gene and protein expression endpoints
- Analytical documentation
- Identity and fraction-profile testing per lot; documentation available on request
- Storage
- Room temperature, dry, sealed and protected from light
Units and conversions
There is no reconstitution step for a solid oral format: the mass per unit of Ventfort (Vascular Bioregulator) is fixed on the label. Where a published method is written in micrograms and the label is in milligrams, the peptide unit converter does the conversion.
Certificate of analysis
Every lot of Ventfort (Vascular Bioregulator) is released against its own lot documentation, and where the manufacturer issues a certificate of analysis for it, that certificate is the record for the lot rather than a generic document for the compound. The lot number on the certificate matches the lot number printed on the label you receive — the vial label itself, where the product is vialled — so the record and the material it describes can always be reconciled.
This listing carries no purity percentage, so none is claimed for it here. Where the manufacturer issues analytical documentation for a lot of this item, it is passed on unaltered — ask and we will send whatever exists.
No lot certificate is on display on this page at the moment. That is a publishing state and not a testing one: lots are released and documented as described above whether or not the document is posted here, and we will send what exists for the lot in stock, or for a lot already on your bench, by its number.
Certificates are available on request before you order as well as after, with no account and no charge. Request the certificate for this listing, read the testing and documentation policy in full, or see how to read a peptide COA.
Questions about Ventfort (Vascular Bioregulator)
What is Ventfort?
Ventfort is the vascular preparation in the Khavinson series of tissue-derived peptide bioregulators. It is a low-molecular-weight peptide complex obtained by fractionating vessel-wall tissue, supplied here as research capsules. It is a mixture characterised by fraction profile, not a single peptide with a defined sequence.
How does Ventfort differ from Vesugen?
Ventfort is the tissue extract; Vesugen is the defined synthetic tripeptide Lys-Glu-Asp assigned to vascular tissue in the same programme. Vesugen can be specified to ≥99% purity with a formula and molecular weight, while Ventfort is documented by fraction profile. Laboratories often study the pair side by side.
Why is there no sequence or molecular weight listed?
Because the material is a mixture of peptide fractions rather than one molecule. Analytical documentation reports identity markers and the distribution of low-molecular-weight fractions, generally below about 10 kDa. Assigning a single formula or sequence to a preparation of this kind would be inaccurate.
What documentation comes with a lot?
Each lot carries documentation of identity and fraction-profile testing, available on request before or after ordering. Because tissue-derived preparations vary between batches more than synthetic peptides do, we recommend recording the lot number alongside experimental data.
How is it prepared for laboratory work?
For in vitro use, capsule contents are taken into water or a physiological buffer, then clarified by centrifugation or filtration so that insoluble excipient is removed before the soluble fraction is added to the assay. Working solutions are best prepared fresh, and the preparation route should be recorded in the protocol.
How strong is the evidence behind the bioregulator series?
Most primary studies come from a small number of Russian laboratories, are published in Russian-language journals, and use small samples with limited independent replication. The proposed mechanism — short peptides influencing tissue-specific gene expression — is a hypothesis under investigation rather than an established one.
